Please login to the form below

Not currently logged in
Email:
Password:

Fanapt

This page shows the latest Fanapt news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs sleep pattern drug for blind

FDA panel backs sleep pattern drug for blind

Polymeropoulos. Vanda previously developed a schizophrenia treatment called Fanapt (iloperidone) which is licensed in North America to Novartis but has failed to make much headway in the market since its launch

Latest news

  • Vanda withdraws EU application for schizophrenia drug Vanda withdraws EU application for schizophrenia drug

    Despite the struggle for approval in the EU, the drug has been available for people with schizophrenia in the US since 2009, where it is sold under the brand name Fanapt.

  • Next generation

    Iloperidone. Fanapt (Novartis). Schizophrenia. US. Levodopa/benserazide. Co-Beneldopa (Teva Pharmaceuticals). Parkinson's disease.

  • US launch for Novartis' Fanapt

    US launch for Novartis' Fanapt. Novartis has launched schizophrenia treatment Fanapt (iloperidone) in the US, for acute treatment of schizophrenia in adults. ... In clinical trials, Fanapt was shown to be effective for the symptoms of schizophrenia.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics